Roquefort Therapeutics plc (ROQ.L)
GBp 3.85
(-10.47%)
GBp 3.85
(-10.47%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 200 Thousand | - | 719.00 |
| Cost of Revenue | - | - | 10.06 Thousand |
| Gross Profit | 200 Thousand | - | -9350.00 |
| Operating Expenses | 2.12 Million | 1.63 Million | 501.41 Thousand |
| Selling, General and Administrative Expenses | 1.5 Million | 940.99 Thousand | 500.71 Thousand |
| Research and Development Expenses | 620.15 Thousand | 319.31 Thousand | 698.00 |
| Other Expenses | - | 373.99 Thousand | - |
| Cost and Expenses | 2.12 Million | 1.63 Million | 511.48 Thousand |
| Operating Income | -1.92 Million | -1.63 Million | -510.76 Thousand |
| Interest Expense | 58.00 | - | - |
| Income Tax Expense | -187.69 Thousand | -18.88 Thousand | -200.92 Thousand |
| Earnings before Tax | -1.93 Million | -1.63 Million | -735.38 Thousand |
| Net Income | -1.74 Million | -1.61 Million | -917.43 Thousand |
| Earnings Per Share Basic | -0.01 | -0.02 | -0.04 |
| Earnings Per Share Diluted | -0.01 | -0.02 | -0.04 |
| Weighted Average Shares Outstanding | 129.14 Million | 103.47 Million | 24.7 Million |
| Weighted Average Shares Outstanding (Diluted) | 129.14 Million | 103.47 Million | 24.7 Million |
| Gross Margin | 1.00 | - | -13.00 |
| EBIT Margin | -9.64 | - | -710.39 |
| Profit Margin | -8.72 | - | -1275.98 |
| EBITDA | -1.92 Million | - | -352.4 Thousand |
| Earnings Before Tax Margin | -9.65 | - | -710.39 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 200 Thousand | - | - | 200 Thousand |
| Cost of Revenue | 8000.00 | 8000.00 | 3890.00 | 2701.00 | - | 1189.00 |
| Gross Profit | -8000.00 | -8000.00 | 196.11 Thousand | -2701.00 | - | 198.81 Thousand |
| Operating Expenses | 331.09 Thousand | 331.09 Thousand | 2.12 Million | -468.71 Thousand | 498.1 Thousand | 1.13 Million |
| Selling, General and Administrative Expenses | 270.58 Thousand | 270.58 Thousand | - | 369.39 Thousand | 369.39 Thousand | 770.81 Thousand |
| Research and Development Expenses | 59.16 Thousand | 59.16 Thousand | - | 127.36 Thousand | 127.36 Thousand | 365.43 Thousand |
| Other Expenses | 1350.00 | 1350.00 | - | -965.47 Thousand | - | - |
| Cost and Expenses | 339.09 Thousand | 339.09 Thousand | 2.13 Million | -468.71 Thousand | 498.1 Thousand | 1.13 Million |
| Operating Income | -339.09 Thousand | -339.09 Thousand | -1.93 Million | 468.71 Thousand | -498.1 Thousand | -937.44 Thousand |
| Interest Expense | - | - | 58.00 | - | - | - |
| Income Tax Expense | 61.64 Thousand | 61.64 Thousand | -187.69 Thousand | 16.3 Thousand | 16.3 Thousand | -155.07 Thousand |
| Earnings before Tax | -351.39 Thousand | -351.39 Thousand | -1.93 Million | -497.39 Thousand | -497.39 Thousand | -937.43 Thousand |
| Net Income | -289.75 Thousand | -289.75 Thousand | -1.74 Million | -481.09 Thousand | -481.09 Thousand | -782.35 Thousand |
| Earnings Per Share Basic | -0.00 | -0.00 | - | -0.00 | -0.00 | -0.01 |
| Earnings Per Share Diluted | -0.00 | -0.00 | - | -0.00 | -0.00 | -0.01 |
| Weighted Average Shares Outstanding | 129.17 Million | 129.17 Million | 129.14 Million | 136.47 Million | 136.47 Million | 121.85 Million |
| Weighted Average Shares Outstanding (Diluted) | 129.14 Million | 129.14 Million | 129.14 Million | 136.44 Million | 136.44 Million | 121.85 Million |
| Gross Margin | - | - | 0.98 | - | - | 0.99 |
| EBIT Margin | - | - | - | - | - | -4.68 |
| Profit Margin | - | - | -8.72 | - | - | -3.91 |
| EBITDA | -337.74 Thousand | -337.74 Thousand | - | -496.75 Thousand | -496.75 Thousand | -936.25 Thousand |
| Earnings Before Tax Margin | - | - | -9.67 | - | - | -4.69 |
600111
RPPINFRA
VIBEF
6914
MMK
NDVNQ